(Ibudilast + bumetanide) is under clinical development by Stalicla and currently in Phase I for Autism Spectrum Disorder (ASD). According to GlobalData, Phase I drugs for Autism Spectrum Disorder (ASD) have a 91% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how (Ibudilast + bumetanide)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
(Ibudilast + bumetanide) overview
A fixed dose combination of ibudilast and bumetanide is under development for the treatment of autism spectrum disorder (ASD) phenotype 1. It is a combination of two repurposed drugs. The drug candidate is administered through oral route. It acts by targeting PDE3, PDE4, PDE10 and Soluble Carrier Family 12 Member 2 (NKCC1) .The drug candidate is being developed based on DEPI (Databased Endophenotyping Patient Identification) technology.
Stalicla overview
Stalicla is a biotechnology company developing precision medicine treatments for patients with Neurodevelopmental disorders. Stalicla is headquartered in Geneva, Switzerland.
For a complete picture of (Ibudilast + bumetanide)’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
